突尼斯不同疫苗接种方案后长期抗 RBD SARS-CoV-2 抗体反应的比较。

Q3 Medicine
Awatef Ben Jemaa, Rihab Bouabsa, Meriam Ben Othmen, Ridha Oueslati, Hamdi Dhaouadi
{"title":"突尼斯不同疫苗接种方案后长期抗 RBD SARS-CoV-2 抗体反应的比较。","authors":"Awatef Ben Jemaa, Rihab Bouabsa, Meriam Ben Othmen, Ridha Oueslati, Hamdi Dhaouadi","doi":"10.62438/tunismed.v102i8.4944","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The study aimed to compare long-term vaccine-induced humoral immunity following different vaccines regimens.</p><p><strong>Methods: </strong>Anti-S-RBD total antibody levels were measured in blood samples of 167 participants nearly 6 months post-vaccination. Participants had received one; two or four doses of Pfizer vaccine or who received a third dose of mRNA vaccine (Pfizer) and primed with mRNA (Pfizer/Moderna), adenoviral (AstraZeneca/Jonson & Jonson) or inactivated (CoronaVac/Sinopharm) vaccine.</p><p><strong>Results: </strong>Among all vaccination regimens, fourth dose of Pfizer achieved the highest S-RBD antibody titers. Nevertheless, the third dose of mRNA vaccine primed with adenoviral vaccine achieved the lowest titers of S-RBD antibody. Notably, the group that received a third dose of mRNA primed with two doses of mRNA vaccine exhibited higher S-RBD antibody compared to groups inoculated with a third dose of mRNA and primed with inactivated or adenovirus vaccine.</p><p><strong>Conclusion: </strong>Our data showed the superiority of three mRNA vaccinations compared to third heterologous vaccine (inactivated of adenoviral) including mRNA as booster in terms of humoral immunogenicity. Our findings supporting the use of additional booster shot from a more potent vaccine type such as mRNA vaccines. Nevertheless, due to the limited number of subjects, it is difficult to extrapolate the results of our study to the whole of Tunisian population. Future studies should investigate a larger cohort and other potential correlates of protection, such as cellular immunity and how it is affected by different vaccination schemes after long-term post-vaccination.</p>","PeriodicalId":38818,"journal":{"name":"Tunisie Medicale","volume":"102 8","pages":"457-464"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390062/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparison of long-term anti-RBD SARS-CoV-2 antibody response following different vaccination schemes in Tunisia.\",\"authors\":\"Awatef Ben Jemaa, Rihab Bouabsa, Meriam Ben Othmen, Ridha Oueslati, Hamdi Dhaouadi\",\"doi\":\"10.62438/tunismed.v102i8.4944\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>The study aimed to compare long-term vaccine-induced humoral immunity following different vaccines regimens.</p><p><strong>Methods: </strong>Anti-S-RBD total antibody levels were measured in blood samples of 167 participants nearly 6 months post-vaccination. Participants had received one; two or four doses of Pfizer vaccine or who received a third dose of mRNA vaccine (Pfizer) and primed with mRNA (Pfizer/Moderna), adenoviral (AstraZeneca/Jonson & Jonson) or inactivated (CoronaVac/Sinopharm) vaccine.</p><p><strong>Results: </strong>Among all vaccination regimens, fourth dose of Pfizer achieved the highest S-RBD antibody titers. Nevertheless, the third dose of mRNA vaccine primed with adenoviral vaccine achieved the lowest titers of S-RBD antibody. Notably, the group that received a third dose of mRNA primed with two doses of mRNA vaccine exhibited higher S-RBD antibody compared to groups inoculated with a third dose of mRNA and primed with inactivated or adenovirus vaccine.</p><p><strong>Conclusion: </strong>Our data showed the superiority of three mRNA vaccinations compared to third heterologous vaccine (inactivated of adenoviral) including mRNA as booster in terms of humoral immunogenicity. Our findings supporting the use of additional booster shot from a more potent vaccine type such as mRNA vaccines. Nevertheless, due to the limited number of subjects, it is difficult to extrapolate the results of our study to the whole of Tunisian population. Future studies should investigate a larger cohort and other potential correlates of protection, such as cellular immunity and how it is affected by different vaccination schemes after long-term post-vaccination.</p>\",\"PeriodicalId\":38818,\"journal\":{\"name\":\"Tunisie Medicale\",\"volume\":\"102 8\",\"pages\":\"457-464\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11390062/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tunisie Medicale\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.62438/tunismed.v102i8.4944\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tunisie Medicale","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.62438/tunismed.v102i8.4944","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

目的:该研究旨在比较不同疫苗方案接种后疫苗诱导的长期体液免疫:方法:对接种疫苗近 6 个月后的 167 名参与者的血液样本进行抗 S-RBD 总抗体水平测定。参与者接种了一剂、两剂或四剂辉瑞疫苗,或接种了第三剂 mRNA 疫苗(辉瑞),并接种了 mRNA(辉瑞/Moderna)、腺病毒(阿斯利康/Jonson & Jonson)或灭活疫苗(CoronaVac/Sinopharm):结果:在所有疫苗接种方案中,第四剂辉瑞疫苗获得的 S-RBD 抗体滴度最高。然而,第三剂以腺病毒疫苗为引物的 mRNA 疫苗获得的 S-RBD 抗体滴度最低。值得注意的是,与接种第三剂 mRNA 并接种灭活疫苗或腺病毒疫苗的组别相比,接种第三剂 mRNA 并接种两剂 mRNA 疫苗的组别表现出更高的 S-RBD 抗体滴度:我们的数据显示,就体液免疫原性而言,接种三剂 mRNA 与接种第三剂异源疫苗(灭活疫苗或腺病毒疫苗)(包括 mRNA 作为加强剂)相比更具优势。我们的研究结果支持使用更强效的疫苗类型(如 mRNA 疫苗)作为额外的加强针。然而,由于受试者人数有限,很难将我们的研究结果推广到整个突尼斯人口中。未来的研究应该调查更大规模的人群和其他潜在的保护相关因素,如细胞免疫,以及不同疫苗接种方案在长期接种后对细胞免疫的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparison of long-term anti-RBD SARS-CoV-2 antibody response following different vaccination schemes in Tunisia.

Aim: The study aimed to compare long-term vaccine-induced humoral immunity following different vaccines regimens.

Methods: Anti-S-RBD total antibody levels were measured in blood samples of 167 participants nearly 6 months post-vaccination. Participants had received one; two or four doses of Pfizer vaccine or who received a third dose of mRNA vaccine (Pfizer) and primed with mRNA (Pfizer/Moderna), adenoviral (AstraZeneca/Jonson & Jonson) or inactivated (CoronaVac/Sinopharm) vaccine.

Results: Among all vaccination regimens, fourth dose of Pfizer achieved the highest S-RBD antibody titers. Nevertheless, the third dose of mRNA vaccine primed with adenoviral vaccine achieved the lowest titers of S-RBD antibody. Notably, the group that received a third dose of mRNA primed with two doses of mRNA vaccine exhibited higher S-RBD antibody compared to groups inoculated with a third dose of mRNA and primed with inactivated or adenovirus vaccine.

Conclusion: Our data showed the superiority of three mRNA vaccinations compared to third heterologous vaccine (inactivated of adenoviral) including mRNA as booster in terms of humoral immunogenicity. Our findings supporting the use of additional booster shot from a more potent vaccine type such as mRNA vaccines. Nevertheless, due to the limited number of subjects, it is difficult to extrapolate the results of our study to the whole of Tunisian population. Future studies should investigate a larger cohort and other potential correlates of protection, such as cellular immunity and how it is affected by different vaccination schemes after long-term post-vaccination.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Tunisie Medicale
Tunisie Medicale Medicine-Medicine (all)
CiteScore
1.00
自引率
0.00%
发文量
72
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信